Clinical Trial

Phase 1 Study of ADX-626 in Healthy Participants

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This first-in-human study will evaluate the safety and tolerability of ADX-626 in healthy participants. The study will also look at how ADX-626 interacts with the human body (the pharmacokinetics and pharmacodynamics of ADX-626).
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-07-15; most recent amendment 2026-06-12.
Status change: Not Yet Recruiting → Recruiting 2025-12-05
Trial Details
NCT Number NCT07081503
Lead Sponsor ADARx Pharmaceuticals, Inc.
Conditions Healthy Adult Participants
Enrollment 44 participants
Start Date 2025-08-12
Primary Completion 2027-01-22 (estimated)
Study Completion 2027-01-22 (estimated)
Updated on ClinicalTrials.gov 2026-07-31